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Cytometry (FCM). The levels of NF-kB p65,phospo-NF-kB p65(p-p65)
and NFATc1 of the VSMCs were determined by Western blot. TRAF6
was blocked by small interfering RNA(siRNA). MTT was used to
observe the cell proliferation. The cell supernatant of IL-2 and IL-6
were tested by ELISA.
RESULTS The level of CD137 was induced by TNF-a in smooth muscle
cells after stimulating 24h(40.002.83 vs 1.000.00,p<0.05). The
cells proliferated when treated with the agonist-CD137 mAb. The
mRNA level of NFATc1 was increased after stimulated by agonist-
CD137 mAb(2.070.09 vs 1.000.00, p<0.05), the protein of NFATc1
was also increased. Simultaneously, the mRNA level of TRAF6 was
also increased(1.390.16 vs 1.000.00,p<0.05) and p-p65 protein was
also increased(p<0.05). When TRAF6 was blocked by TRAF6 siR-
NA,the expression of p-p65 and NFATc1 was decreased after stimu-
lated by agonist-CD137 mAb compared with the stimulated
group(1.150.07 vs 2.070.09, p < 0.05). Pretreated the VSMCs with
PDTC(30mmol/L) after 30min,the expression of p-p65 was inhibited in
cytoplasm and nucleus,we stimulated the cells by agonist-CD137mAb
at this time,the mRNA level of NFATc1 was also suppressed(1.150.07
vs 2.070.09, p < 0.05) and the NFATc1 protein was inhibited(p <
0.05). The cell supernatant of IL-2 and IL-6 went up by agonist-CD137
mAb(0.910.1 vs 1.290.17,p<0.05;0.510.04 vs 0.610.07,p<0.05),
and decreased when NFATc1 was silenced(1.290.23 vs 1.000.00,
p<0.05;0.610.07 vs 0.500.03,p<0.05).
CONCLUSIONS These results demonstrates that CD137 can be induced
by TNF-a in VSMCs, and the CD137 may signaling affect the expression
of NFATc1 in mice VSMCs through TRAF6/NF-kB pathway.
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Intracoronary Cardiosphere-Derived Cells for Heart Regeneration After
Myocardial Infarction
Jie Qin, Yuefei Guo, Xiuzhen Chen, Xuelian Liu
Department of Radiology, the Third Afﬁliated Hospital of Sun Yat-sen
University
OBJECTIVES We aimed to assess safety of therapy with cardiosphere-
derived cells (CDCs) in patients with left ventricular dysfunction after
myocardial infarction.
METHODS An independent data coordinating center randomly allo-
cated patients in a 2:1 ratio to receive CDCs or standard care. For pa-
tients assigned to receive CDCs, autologous cells grown from
endomyocardial biopsy specimens were infused into the infarct-
related artery 1$5-3 months after myocardial infarction. The primary
endpoint was proportion of patients at 6 months who died due to
ventricular tachycardia, ventricular ﬁbrillation, or sudden unexpected
death, or had myocardial infarction after cell infusion, new cardiac
tumor formation on MRI, or a major adverse cardiac event. We also
assessed preliminary efﬁcacy endpoints on MRI by 6 months.
RESULTS Between May 1, 2009, and Dec 30, 2014, we randomly
allocated 31 eligible participants of whom 25 were included in a per-
protocol analysis. Mean baseline left ventricular ejection fraction
(LVEF) was 39% (SD 12) and scar occupied 24% (10) of left ventricular
mass. Biopsy samples yielded prescribed cell doses within 36 days (SD
6). No complications were reported within 24 h of CDC infusion. By 6
months, no patients had died, developed cardiac tumors, or MACE in
either group. Four patients (24%) in the CDC group had serious
adverse events compared with one control (13%; p¼1.00). Compared
with controls at 6 months, MRI analysis of patients treated with CDCs
showed reductions in scar mass (p¼0.001), increases in viable heart
mass (p¼0.01) and regional contractility (p¼0.02), and regional sys-
tolic wall thickening (p¼0.015). However, changes in end-diastolic
volume, end-systolic volume, and LVEF did not differ between groups
by 6 months.
CONCLUSIONS Intracoronary infusion of autologous CDCs after
myocardial infarction is safe and effective, warranting the expansion
of such therapy to phase 2 study.
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ITRAQ-Based Quantitative Proteomic Analysis of Heart in a Rat Model of
Exhaustive Training
Haiyan Liu, Xuebin Cao
No. 252 Hospital of PLA
OBJECTIVES To explore the presence of informative protein bio-
markers in the rat cardiac between the health group and exhausting
group, The purpose of this study is to understand the difference inprotein expression patterns between health and after exhaustive
swimming and to evaluate the protein contributions to exhaustive
training.
METHODS 20 male SD rats (male, the weight is 20020g, SPF) were
randomly divided two groups, health group and exhausting group.
The rats of exhausting group were swimming in the artiﬁcial pond, get
the swimming method result in a model of Single Bout of Exhaustive
Swimming in Rats. After exhaustive swimming the hearts were
collected immediately. We mainly adopted advanced 8-plex ITRAQ
coupled with 2D LC-MS/MS technology for proteomics.
RESULTS Analysis of proteomic data found that 122 proteins were
identiﬁed with quantitative information between the two groups, of
with the expression level of 69 proteins had signiﬁcant differences at
least, compared with the health group(ratio＞1.2 or ＜0.7, and P ＜
0.05) ,of which 50 proteins were up-regulated, 19 proteins down-
regulated.
CONCLUSIONS This study provided a global view of potential
mechanisms and potential biomarkers of heart, and demonstrated
that iTRAQ combined with 2D LC-MS/MS quantitative proteomics is a
powerful tool for biomarker discovery.
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Exendin-4, An Gulcagon-like Peptide 1 Analogue, Attenuates
Cardiomyocyte Hypertrophy Via AMPK/mTOR Pathway
Yue Zhou, Xin He, Yiyi Huang, Yili Chen, Jiangui He
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University
OBJECTIVES Cardiac hypertrophy is the pathological basis of the
development of various cardiovascular diseases and is a major inde-
pendent risk factor of cardiovascular morbidity and mortality.
Glucagon-like peptide 1 (GLP-1), an incretin peptide released from the
intestine, exerts various cardioprotective actions and is proved to
contribute in the regulation of cardiac functions. However, the role of
Exendin-4, a stable GLP-1 analogue, in the cardiac hypertrophy re-
mains unclear.
METHODS 1. Primary neonatal ventricular cardiomyocytes were
cultured to establish the model of cardiomyocyte hypertrophy
induced by phenylephrine (PE).
2. RNA isolation and quantitative real-time PCR (q-PCR) were per-
formed to evaluate the transcriptional level of hypertrophic markers
such as ANP BNP and beta-MHC.
3. Western Blotting was carried out to observe the change of the
signaling pathway proteins levels.
4. The cardiomyocyte morphological change was manifested by
Immunoﬂuorescence staining and measurement of the cell surface
area.
RESULTS Our study demonstrated that exendin-4 attenuated cardiac
hypertrophy induced by phenylephrine (PE), manifested by decreased
hypertrophic markers such as ANP, BNP, beta-MHC and cell surface.
Phosphorylated extracellular signal regulated protein kinase (phos-
pho-ERK1/2) and phosphor-p38 mitogen-activated protein kinase
(MAPK) protein levels didn’t change in the team treated by exendin-4
and PE. In addition, we discovered that exendin (9-39), a GLP-1 re-
ceptor antagonist, can remove the anti-hypertrophic effect of exen-
din-4, evidently. Moreover, we showed that the anti-hypertrophic
effect of exendin-4 was also signiﬁcantly reversed by compound C, an
AMPK inhibitor, and rapamycin, a selective blocker of mTOR.
CONCLUSIONS These results demonstrate that exendin-4 inhibit
cardiac hypertrophy induced by PE via AMPK/mTOR pathway.
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Vascular Adventitia Calciﬁcation and its Underlying Mechanism
Na Li, Wenli Cheng
China-Japan Friendship Hospital
OBJECTIVES Previous research on vascular calciﬁcation has mainly
focused on the vascular intima and media. However, we show here
that vascular calciﬁcation may also occur in the adventitia as well. The
purpose of this work is to help elucidate the pathogenic mechanisms
underlying vascular calciﬁcation.
METHODS Mice were fed high fat diets (HFD) for 48 weeks, observing
calciﬁed lesions. Also included in this study were human subjects
aged 60 years and older that had died of coronary heart disease, heart
failure or renal failure, observing calciﬁed lesions. Explant culture of
ﬁbroblasts, the primary cell type comprising the adventitia, was
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which comprise only a small percentage of all cells in the adventitia,
in calcifying medium resulted in calciﬁcation.
RESULTS Following 48 weeks, calciﬁed lesions were observed in the
aorta adventitia and coronary artery adventitia of ApoE-/-mice. Von
Kossa staining showed calciﬁcation in the human aorta adventitia.
Explant culture of ﬁbroblasts, was successfully induced for calciﬁca-
tion after incubation with TGF-b1 (20 ng/ml) þ mineralization media
for 4 days, and the phenotype conversion of vascular adventitial ﬁ-
broblasts into myoﬁbroblasts was identiﬁed. Culture of smooth mus-
cle cells (SMCs), which comprise only a small percentage of all cells in
the adventitia, in calcifying medium for 14 days resulted in signiﬁcant
calciﬁcation.
CONCLUSIONS Vascular calciﬁcation can occur in the adventitia.
The conversion of ﬁbroblasts into myoﬁbroblasts may contribute
to the calciﬁcation process. Although SMCs comprise only a small
percentage of the entire adventitia cell population, they may also
contribute.
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in the Early Phase After Vascular Injury
Hang Wang,1 Keyin Cai,1 Li Wang,1 Kehong Zhao,1 Ying Tu,1
Xiao Wang,1 Jiahuan Li,1 Hao Huang2
1Cadre Ward Two, Wuhan General Hospital of Guangzhou Military
Command, Wuhan 430070, China; 2Clinic center, Shenzhen Hornetcorn
Biotechnology Crop. Shenzhen 518400, China
OBJECTIVES Endothelial progenitor cells (EPCs) play important roles
in the process of reendothelialization and prevent neointimal forma-
tion after vascular injury. Sphingosine-1-phosphate (S1P) can via
the sphingosine-1-phosphate receptor 3 (S1PR3) induce pro-
liferation,migration and angiogenesis of EPCs. This study aims to
investigate effects of transplantation of EPCs overexpressing S1PR3 on
reendothelialization and neointimal formation in response to vascular
injury in mice.
METHODS Spleen-derived EPCs were cultured and expanded in
endothelial basal medium. EPCs were infected with lentivirus vectors
expressing mice S1PR3 (S1PR3- EPCs)or green ﬂuorescent protein(GFP-
EPCs). Three days after gene transfection, the mRNA level and protein
level of S1PR3 were assayed. Mice were administered 200 mL saline
alone or 200 mL saline containing ﬂuorescently labeled EPCs (1  106)
or ﬂuorescently labeled EPCs with expressing S1PR3 (1  106) via tail
vein injection directly after wire-mediated carotid artery injury and
again after 24 h. 14 days after transplantation, cell tracking showed
that transfused EPCs could homeing to the sites of endothelial injury.
RESULTS At day 7, the reendothelialized area in the S1PR3- EPCs
transplanted arteries (56.32  6.33%) was signiﬁcantly larger than that
in the GFP- EPCs transplanted arteries (42.474.69%; p<0.05) and that
in the saline control group (28.31  7.32%, p<0.01). At day 14, the
reendothelialized area in the S1PR3- EPCs transplanted arteries (72.28
8.37%) was signiﬁcantly larger than that in the GFP- EPCs transplanted
arteries (50.21  5.66%, p<0,01) and that in the saline control group
(29.98  7.58%, p<0.01). At day 14, a signiﬁcant decrease (P < 0.05) in
neointimal /media (NI/M )ratiowas noted in the S1PR3- EPCs group (0.31
 0.02) as compared with that in the GFP- EPCs group (0.45 0.10) and
in the saline control group (0.770.21). Our results showed that EPCs
overexpressing S1PR3 signiﬁcantly accelerates reendothelialization
and mitigates neointimal formation in the early phase after carotid ar-
tery injury in mice.
CONCLUSIONS Our data suggest that transplantation of EPCs over-
expressing S1PR3 can have a combined effect of both amplifying the
reendothelialization capacity of EPCs and inhibiting neointima for-
mation so as to facilitate better inhibition of adverse remodeling after
vascular injury. Therefore, gene modiﬁed EPCs may be applied in
clinical progenitor cell therapy to improve vascular repair after
vascular injury.
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Aberrant Expression of Circular RNAs in Endothelial Dysfunction
Yuqiang Ji, Manli Cheng
First hospital of Xi’an
OBJECTIVES The aim of this study was to determine the expression
proﬁle of circular RNAs (circRNAs) in oxidized low-density lipoprotein(ox-LDL) treated human umbilical vein endothelial cells (HUVECs)
compared with normal HUVECs through human circRNA microarray
and predict their miRNA binding sites.
METHODS The global circRNAs expression proﬁles in ox-LDL treated
HUVECs compared with normal HUVECs were measured by the
Arraystar Human circRNA Array (8x15K, Arraystar). Agilent Feature
Extraction software (version 11.0.1.1) was used to analyze acquired
array images. The circRNA/microRNA interaction was predicted with
Arraystar’s home-made miRNA target prediction software.
RESULTS Compared with normal HUVECs, 24 circRNAs were different
expression (fold change1.5, p-value cut-off is 0.05) in ox-LDL treated
HUVECs. 15 circRNA were up-regulated and 9 circRNAs were down-
regulated. The most up-regulated circRNA was circRNA-104137 and
the most down-regulated circRNA was circRNA-100188. The miRNA
binding sites of circRNA-104137 were miR-455-3p, miR-218-1-3p, miR-
423-5p, miR-503-5p and miR-223-3p. The miRNA binding sites of
circRNA-100188 were miR-637, miR-608, miR-328-5p, miR-877-3p and
miR-185-3p.
CONCLUSIONS The aberrantly expression proﬁle of circRNAs in ox-
LDL treated HUVECs compared with normal HUVECs indicates the
potential roles of circRNAs in endothelial dysfunction. This study may
provide new insights into the mechanism and potential targets for the
endothelial dysfunction.GW26-e1596
Effects of atorvastatin on mRNA and protein expression of adropin in
cultured human umbilical endothelial cells and rat artery smooth
muscle cells
Liangping Zhao, Chengjia Zhang, Li Wang, Tao You, Weiting Xu,
Jianchang Chen
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OBJECTIVES Adropin is a newly-identiﬁed secretary protein that
participates in the regulation of energy homeostasis and insulin
response. Growing published evidence presented the beneﬁcial as-
sociation of adropin with coronary artery disease. A laboratory test
showed the beneﬁcial effects of adropin on endothelial cells prolif-
eration and migration. The endothelial cell dysfunction and prolifer-
ation of vascular smooth muscle cell form the core mechanism of
atherosclerosis. Therefore, to increase the expression of adropin by
some therapy may play a role in the prevention and treatment of
atherosclerosis. In the present study, the effects of atorvastatin on
mRNA and protein expression of adropin in cultured human umbilical
vein endothelial cells (HUVEC) and rat artery smooth muscle cell
(RASMC) were investigated.
METHODS HUVEC and RASMC were cultured in vitro with atorvas-
tatin of 0.002, 0.02, 0.2, 2 and 20 umol/L for 6, 12 and 24 hours (h).
The proliferation of HUVEC and RASMC were detected by MTT chro-
matometry. RT-PCR, and ELISA were performed to present the
expression of adropin mRNA and adropin protein respectively.
RESULTS The proliferation of HUVEC was promoted after co-incu-
bation with atorvastain from 0.002 to 20 umol/L concentration, and
the peak was at 20umol/L (versus control, P<0.05) and 24 h (versus
6 h, P<0.05). Atorvastatin upregulated the expression of adropin
mRNA and adropin protein dose-dependently and time-dependently
in HUVEC with a peak at 20umol/L (versus control, P<0.01) and 24
h (versus 6 h, P<0.01). Adropin protein concentration in culture
medium was positively correlated with the OD value indicating
proliferation at 12 h (P¼0.001) and 24 h (P<0.001) after co-
incubation.
The proliferation of RASMC was decreased after co-incubation with
atorvastain from 0.002 to 20umol/L concentration, and the valley
was at 20umol/L (versus control, P<0.05) and 24 h (versus 6 h,
P<0.05). Atorvastatin upregulated the expression of adropin mRNA
and adropin protein in RASMC with a peak at 0.02 umol/L (versus
control and 20 umol/L, P<0.05) and 24 h (versus 6 h, P<0.01).
Adropin protein concentration in culture medium was positively
correlated with the OD value at 12 h (P¼0.002) and 24 h (P¼0.001)
after co-incubation.
CONCLUSIONS Atorvastatin promoted the expression of adropin in
HUVEC and RASMC at a appropriate range of concentration, with the
corresponding results that proliferation of HUVEC was promoted but
RASMC proliferation was inhibited in the test concentration range of
atorvastatin.
